Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals

Journal of Virological Methods

Volumn 155, Issue 2, 2009, Pages 143-149

  Chris Maple, P A ^a   Gunn, Annabel ^a   Sellwood, Jane ^b   Brown, David W G ^a   Gray, Jim J ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Commercial enzyme immunoassays; Serology; Time resolved fluorescence immunoassay; Varicella zoster virus

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE PERSONNEL; HEART GRAFT; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; KIDNEY FAILURE; LATEX AGGLUTINATION TEST; LEUKEMIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; VARICELLA ZOSTER VIRUS;

ADULT; ANTIBODIES, VIRAL; CHICKENPOX; CHILD; CHILD, PRESCHOOL; FLUOROIMMUNOASSAY; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MASS SCREENING; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

HUMAN HERPESVIRUS 3;

EID: 57749200263     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.09.032     Document Type: Article

References (22)

1. Arvin A.M. Varicella vaccine-the first six years. N. Engl. J. Med. 344 (2001) 1007-1009
2. Breuer J. Vaccination to prevent varicella and shingles. J. Clin. Pathol. 54 (2001) 743-747
3. De Ory F., Echevarria J.M., Kafatos G., Anastassopoulou C., Andrews N., et al. European seroepidemiology network 2: standardization of assays for seroepidemiology of varicella zoster virus. J. Clin. Virol. 36 (2006) 111-118
4. Department of Health. In: Salisbury D., Ramsay M., and Noakes K. (Eds). Immunisation Against Infectious Disease (2006), The Stationary Office, London
5. Enders G., Miller E., Cradock-Watson J., Bolley I., and Ridehaigh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343 (1994) 1548-1551
6. Gnann J.W., and Whitley R.J. Herpes Zoster. N. Engl. J. Med. 347 (2002) 340-346
7. Grandien M., Appelgren P., Espmark A., and Hanngren K. Determination of varicella immunity by the indirect immunofluorescence test in urgent clinical situations. Scand. J. Infect. Dis. 8 (1976) 65-69
8. Jerant A.F., DeGaetano J.S., Epperly T.D., Hannapel A.C., Miller D.R., and Lloyd A.J. Varicella susceptibility ad vaccination strategies in young adults. J. Am. Board Fam. Pract. 11 (1998) 296-306
9. Krah D.L. Assays for antibody to varicella zoster virus. Infect. Dis. Clin. N. Am. 10 (1996) 507-525
10. Landry M.L., Cohen S.D., Mayo D.R., Fong C.K., and Andiman W.A. Comparison of fluroresent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus. J. Clin. Microbiol. 25 (1987) 832-835
11. Larussa P., Steinberg S., Waithe E., Hanna B., and Holzman R. Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test. J. Clin. Microbiol . 25 (1987) 2059-2062
12. MacMahon E., Brown L.J., Bexley S., Snashall D.C., and Patel D. Identification of potential candidates for varicella vaccination by history: questionnaire and seroprevalence study. BMJ 329 (2004) 551-552
13. Maple P.A.C., Gray J., Breuer J., Kafatos G., Parker S., and Brown D. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin. Vaccine Immunol. 13 (2006) 214-218
14. Maple, P.A.C., Gray, J., Brown, D., under review. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring immunity following natural infection. J. Virol. Methods.
15. Martins T.B., Jaskowski T.D., Schroder C., Streeter B., and Hill H.R. Comparison of three commercially available assays for detection of varicella-zoster virus antibody. Clin. Diagn. Lab. Immunol. 1 (1994) 186-188
16. Miller E., Marshall R., and Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev. Med. Microbiol. 4 (1993) 222-230
17. Sauerbrei A., and Wutzler P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J. Clin. Microbiol. 44 (2006) 3094-3097
18. Steinberg S.P., and Gershon A.A. Measurement of antibodies to Varicella-Zoster virus by using a latex agglutination test. J. Clin. Microbiol. 29 (1991) 1527-1529
19. Vyse A.J., Gay N.J., Hesketh L.M., Morgan-Capne P., and Miller E. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. Epidemiol. Infect. 132 (2004) 1129-1134
20. Weinberg A., Hayward A.R., Masters H.B., Ogu I.A., and Levin M.J. Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell mediated immunity. J. Clin. Microl. 34 (1996) 445-446
21. Williams V., Gershon A.A., and Brunell P.A. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J. Infect. Dis. 130 (1974) 669-672
22. Wreghitt T.G., Tedder R.S., Nagington J., and Ferns R.B. Antibody assays for Varicella-Zoster virus: comparison of competitive enzyme-linked immunosorbent assay (ELISA), competitive radioimmunoassay (RIA), complement fixation and indirect immunofluorescence assays. J. Med. Virol. 13 (1984) 361-370